Literature DB >> 28259440

Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity.

James P Strassner1, Mehdi Rashighi1, Maggi Ahmed Refat2, Jillian M Richmond1, John E Harris3.   

Abstract

BACKGROUND: Vitiligo is an autoimmune disease of the skin with limited treatment options; there is an urgent need to identify and validate biomarkers of disease activity to support vitiligo clinical studies.
OBJECTIVE: To investigate potential biomarkers of disease activity directly in the skin of vitiligo subjects and healthy subjects.
METHODS: Patient skin was sampled via a modified suction-blister technique, allowing for minimally invasive, objective assessment of cytokines and T-cell infiltrates in the interstitial skin fluid. Potential biomarkers were first defined and later validated in separate study groups.
RESULTS: In screening and validation, CD8+ T-cell number and C-X-C motif chemokine ligand (CXCL) 9 protein concentration were significantly elevated in active lesional compared to nonlesional skin. CXCL9 protein concentration achieved greater sensitivity and specificity by receiver operating characteristic analysis. Suction blistering also allowed for phenotyping of the T-cell infiltrate, which overwhelmingly expresses C-X-C motif chemokine receptor 3. LIMITATIONS: A small number of patients were enrolled for the study, and only a single patient was used to define the treatment response.
CONCLUSION: Measuring CXCL9 directly in the skin might be effective in clinical trials as an early marker of treatment response. Additionally, use of the modified suction-blister technique supports investigation of inflammatory skin diseases using powerful tools like flow cytometry and protein quantification.
Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD8; CXCL10; CXCL9; autoimmunity; biomarkers; biopsy; blisters; inflammatory skin disease; suction blister; vitiligo

Mesh:

Substances:

Year:  2017        PMID: 28259440      PMCID: PMC5392432          DOI: 10.1016/j.jaad.2016.12.021

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  25 in total

1.  Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Ann Transl Med       Date:  2015-12

2.  Suction blister epidermal grafting versus punch skin grafting in recalcitrant and stable vitiligo.

Authors:  S Gupta; V K Jain; P K Saraswat
Journal:  Dermatol Surg       Date:  1999-12       Impact factor: 3.398

3.  Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes.

Authors:  Xingfeng Bao; E Ashley Moseman; Hideo Saito; Bronislawa Petryniak; Bronislawa Petryanik; Aude Thiriot; Shingo Hatakeyama; Yuki Ito; Hiroto Kawashima; Yu Yamaguchi; John B Lowe; Ulrich H von Andrian; Minoru Fukuda
Journal:  Immunity       Date:  2010-11-24       Impact factor: 31.745

4.  Interstitial fluid: exchange of macromolecules between plasma and skin interstitium.

Authors:  N Rossing; A M Worm
Journal:  Clin Physiol       Date:  1981-06

5.  Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Silvia Frascerra; Fabio Galetta; Ferdinando Franzoni; Alda Corrado; Mario Miccoli; Salvatore Benvenga; Aldo Paolicchi; Ele Ferrannini; Poupak Fallahi
Journal:  Cytokine       Date:  2011-05-20       Impact factor: 3.861

6.  Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo.

Authors:  T Caixia; F Hongwen; L Xiran
Journal:  J Dermatol Sci       Date:  1999-09       Impact factor: 4.563

Review 7.  Overview of the mechanisms regulating chemokine activity and availability.

Authors:  Anneleen Mortier; Jo Van Damme; Paul Proost
Journal:  Immunol Lett       Date:  2012-07-30       Impact factor: 3.685

8.  Punch grafting versus suction blister epidermal grafting in the treatment of stable lip vitiligo.

Authors:  Aravind Babu; Devinder Mohan Thappa; Telanseri J Jaisankar
Journal:  Dermatol Surg       Date:  2007-12-17       Impact factor: 3.398

9.  Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease.

Authors:  Jillian M Richmond; Dinesh S Bangari; Kingsley I Essien; Sharif D Currimbhoy; Joanna R Groom; Amit G Pandya; Michele E Youd; Andrew D Luster; John E Harris
Journal:  J Invest Dermatol       Date:  2016-09-26       Impact factor: 8.551

10.  Elevated homocysteine levels in suction-induced blister fluid of active vitiligo lesions.

Authors:  Tag Anbar; Nehal Mohamed Zuel-Fakkar; Mary Fikry Matta; Mai Mohammed Ibrahim Arbab
Journal:  Eur J Dermatol       Date:  2016 Jan-Feb       Impact factor: 3.328

View more
  23 in total

Review 1.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 2.  The Role of Memory CD8+ T Cells in Vitiligo.

Authors:  Rebecca L Riding; John E Harris
Journal:  J Immunol       Date:  2019-07-01       Impact factor: 5.422

3.  Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

Authors:  Lucy Y Liu; James P Strassner; Maggi A Refat; John E Harris; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

Review 4.  The convergence theory for vitiligo: A reappraisal.

Authors:  Roopal V Kundu; Julia M Mhlaba; Stephanie M Rangel; I Caroline Le Poole
Journal:  Exp Dermatol       Date:  2018-06-28       Impact factor: 3.960

5.  scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in Treg function.

Authors:  Kyle J Gellatly; James P Strassner; Kingsley Essien; Maggi Ahmed Refat; Rachel L Murphy; Anthony Coffin-Schmitt; Amit G Pandya; Andrea Tovar-Garza; Michael L Frisoli; Xueli Fan; Xiaolan Ding; Evangeline E Kim; Zainab Abbas; Patrick McDonel; Manuel Garber; John E Harris
Journal:  Sci Transl Med       Date:  2021-09-08       Impact factor: 17.956

6.  Association of Clinical Markers With Disease Progression in Patients With Vitiligo From China.

Authors:  Li Zhang; Shujun Chen; Yuli Kang; Xiuxiu Wang; Fang Yan; Min Jiang; Qianqian Wang; Ziqi Liu; Chengfeng Zhang; Leihong Xiang
Journal:  JAMA Dermatol       Date:  2020-03-01       Impact factor: 10.282

7.  Mouse Model for Human Vitiligo.

Authors:  Rebecca L Riding; Jillian M Richmond; John E Harris
Journal:  Curr Protoc Immunol       Date:  2018-09-25

8.  Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Lucio Zapata; Madhuri Garg; Rebecca L Riding; Maggi A Refat; Xueli Fan; Vincent Azzolino; Andrea Tovar-Garza; Naoya Tsurushita; Amit G Pandya; J Yun Tso; John E Harris
Journal:  Sci Transl Med       Date:  2018-07-18       Impact factor: 17.956

Review 9.  Myron Gordon Award paper: Microbes, T-cell diversity and pigmentation.

Authors:  I Caroline Le Poole
Journal:  Pigment Cell Melanoma Res       Date:  2021-01-27       Impact factor: 4.159

10.  Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy.

Authors:  Rebecca L Riding; Jillian M Richmond; Keitaro Fukuda; John E Harris
Journal:  Pigment Cell Melanoma Res       Date:  2020-10-26       Impact factor: 4.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.